Efficacy evaluation of entomological drug Adenoprosin® usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement

Abstract

BACKGROUND: Increasing the effectiveness of treatment of patients with symptoms of the lower urinary tract is one of the main problems of modern urology, which is associated both with their high prevalence and with a significant deterioration in the quality of life of patients.

AIM: The article presents the results of the usage of the entomological drug Adenoprosin® in the combined treatment of patients with lower urinary tract symptoms due to benign prostatic enlargement.

MATERIALS AND METHODS: 80 patients were treated (mean age 63.6 ± 6.4 years). At the initial phase of the study, all patients received Tamsulosin 0.4 mg once a day for 4 weeks. At the second phase, the patients were divided into two groups. Group 1 patients were prescribed a combination therapy with Adenoprosin (1 rectal suppository (150 mg) at night, for a course of 30 suppositories) and Tamsulosin (0.4 mg per day). Patients of the 2^nd group continued monotherapy with Tamsulosin (0.4 mg per day). The duration of the second phase of treatment was 4 weeks.

RESULTS: The results of the study showed a more pronounced positive dynamics of clinical indicators in patients of the 1^st group, who received combination therapy with Adenoprosin and Tamsulosin, compared to patients of the 2^nd group. There was a more pronounced decrease in the IPSS score, an improvement in the quality of life, an increase in the urine flow rate and a decrease in the volume of residual urine. The volume of the prostate gland did not change significantly. When examined 2 weeks after the end of treatment, the positive dynamics of clinical indicators in patients of the 1^st group persisted. The tolerability of the treatment was satisfactory in patients of both groups.

CONCLUSIONS: The results of the study indicate the advisability of including Adenoprosin in the combination therapy of patients with lower urinary tract symptoms due to benign enlargement of the prostate gland.

Keywords

entomotherapy / lower urinary tract symptoms / benign prostatic enlargement / benign prostatic hyperplasia / Adenoprosin®

References

[1] Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722–728. DOI: 10.1111/bju.15286

[2] Launer B.M., McVary K.T., Ricke W.A., Lloyd G.L. The rising worldwide impact of benign prostatic hyperplasia // BJU Int. 2021. Vol. 127, No. 6. P. 722–728. DOI: 10.1111/bju.15286

[3] Xu XF, Liu GX, Guo YS, et al. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Mens Health. 2021;15(4):15579883211036786. DOI: 10.1177/15579883211036786

[4] Xu X.F., Liu G.X., Guo Y.S., et al. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019 // Am J Mens Health. 2021. Vol. 15, No. 4. P. 15579883211036786. DOI: 10.1177/15579883211036786

[5] Kalinina SN, Burlaka OO, Aleksandrov MS, Vydryn PS. Diagnosis and treatment of lower urinary tract symptoms and erectile dysfunction in patients with benign prostate hyperplasia. Urologicheskie vedomosti. 2018;8(1):2633. (In Russ.) DOI: 10.17816/uroved8126-33

[6] Калинина С.Н., Бурлака О.О., Александров М.С., Выдрин П.С. Диагностика и лечение симптомов нижних мочевых путей и эректильной дисфункции у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. 2018. Т. 8, № 1. С. 26–33. DOI: 10.17816/uroved8126-33

[7] Wei J, Calhoun E, Jacobsen S. Urologic diseases in America project: BPH. J Urol. 2005;173(4):1256–1261. DOI: 10.1097/01.ju.0000155709.37840.fe

[8] Wei J., Calhoun E., Jacobsen S. Urologic diseases in America project: BPH // J Urol. 2005. Vol. 173, No. 4. P. 1256–1261. DOI: 10.1097/01.ju.0000155709.37840.fe

[9] Gratzke C, Schlenker B, Seitz M, Kar A, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol. 2007;177:1419. DOI: 10.1016/j.juro.2006.11.062

[10] Gratzke C., Schlenker B., Seitz M., Kar A., et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study // J Urol. 2007. Vol. 177. P. 1419. DOI: 10.1016/j.juro.2006.11.062

[11] Rasner PI, Pushkar’ DYu. Lechenie simptomov nizhnikh mochevykh putei u patsientov s dobrokachestvennoi giperplaziei predstatel’noi zhelezy: sovremennye mezhdunarodnye standarty. Spravochnik poliklinicheskogo vracha. 2015;(10):20–26. (In Russ.)

[12] Раснер П.И., Пушкарь Д.Ю. Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты // Справочник поликлинического врача. 2015. № 10. С. 20–26.

[13] Kasyan GR, Konovalov IV. Current opportunities for combination treatment of lower urinary tract symptoms due to benign prostatic hyperplasia in men. Issledovaniya i praktika v meditsine 2016;3(2):37–44. (In Russ.) DOI: 10.17709/2409-2231-2016-3-2-5

[14] Касян Г.Р., Коновалов И.В. Современные возможности комбинированной терапии симптомов нижних мочевыводящих путей на фоне доброкачественной гиперплазии предстательной железы у мужчин // Исследования и практика в медицине. 2016. Т. 3, № 2. С. 37–44. DOI: 10.17709/2409-2231-2016-3-2-5

[15] Zitoun OA, Farhat AM, Mohamed MA, Hamad MR, et al. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors. Eur J Pharmacol. 2020;883:173301 DOI: 10.1016/j.ejphar.2020.173301

[16] Zitoun O.A., Farhat A.M., Mohamed M.A., Hamad M.R., et al. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors // Eur J Pharmacol. 2020. Vol. 883. P. 173301 DOI: 10.1016/j.ejphar.2020.173301

[17] Kuzmin IV, Ajub AK, Slesarevskaya MN. Phos phodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions. Urology reports (St. Petersburg). 2020;10(1):67–74. (In Russ.) DOI: 10.17816/uroved10167-74

[18] Кузьмин И.В., Аюб А.Х., Слесаревская М.Н. Ингибиторы фосфодиэстеразы 5-го типа в лечении дисфункций нижних мочевых путей // Урологические ведомости. 2020. Т. 10, № 1. C. 67–74. DOI: 10.17816/uroved10167-74

[19] Al-Shukri AS, Kostyukov SV. Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement. Urology reports (St. Petersburg). 2020;10(4):317–323. (In Russ.) DOI: 10.17816/uroved48969

[20] Аль-Шукри А.С., Костюков С.В. Возможности фитотерапии в лечении пациентов с симптомами нижних мочевых путей вследствие доброкачественного увеличения предстательной железы // Урологические ведомости. 2020. Т. 10, № 4. C. 317–323. DOI: 10.17816/uroved48969

[21] Gravas S, Cornu JN, Gacci M, et al. Management of Non-neurogenic Male LUTS [internet]. Guideline of European Association of Urology, 2021. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5

[22] Gravas S., Cornu J.N., Gacci M., et al. Management of Non-neurogenic Male LUTS [internet]. Guideline of European Association of Urology, 2021. Режим доступа: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5. Дата обращения: 20.12.2021.

[23] Al-Shukri SH, Gorbachev AG, Borovets SJ, et al. Vlijanie prostatilena na rasstrojstva mocheispuskanija u bol’nyh dobrokachestvennoj giperplaziej predstatel’noj zhelezy. Urologiia. 2005;(5):25–26. (In Russ.)

[24] Аль-Шукри С.X., Горбачев А.Г., Боровец С.Ю., и др. Влияние простатилена на расстройства мочеиспускания у больных доброкачественной гиперплазией предстательной железы // Урология. 2005. № 5. С. 25–26.

[25] Bej-Bienko GYA. Obshchaya entomologiya. Moscow: Vysshaya shkola; 1966. 496 p. (In Russ.)

[26] Бей-Биенко Г.Я. Общая энтомология. Москва: Высшая школа, 1966. 496 c.

[27] Romanenko VN, Meditsinskaya arakhnoentomologiya. Tomsk: Izdatel’skii Dom Tomskogo gosudarstvennogo universiteta; 2015. 283 p. (In Russ.)

[28] Романенко В.Н. Медицинская арахноэнтомология. Томск: Издательский Дом Томского государственного университета, 2015. 283 c.

[29] Kolesnikova EA, Brusnigina NF, Efimov EI. Evaluation of the prevalence of antibiotic-resistant strains of genital mycoplasms, isolated in men with inflammatory urogenital diseases. RMJ Medical Review. 2018:2(1):4–7. (In Rus.)

[30] Колесникова Е.А., Бруснигина Н.Ф., Ефимов Е.И. Оценка распространенности антибиотикорезистентных штаммов генитальных микоплазм, выделенных у мужчин с воспалительными заболеваниями урогенитального тракта // РМЖ. Медицинское обозрение. 2018. Т. 1, № 2. С. 4–7.

[31] Kadyrov ZA, Stepanov VS, Faniev MV. Possibilities of entomological drugs in the symptomatic and pathogenetic therapy of benign prostatic hyperplasia and chronic abacterial prostatitis. Andrology and Genital Surgery 2020;21(3):69–74. (In Russ.) DOI: 10.17650/2070-9781-2020-21-3-69-74

[32] Кадыров З.А., Степанов В.С., Фаниев М.В. Возможности энтомологических лекарств в симптоматической и патогенетической терапии доброкачественной гиперплазии предстательной железы и хронического абактериального простатита// Андрология и генитальная хирургия. 2020. Т. 21, № 3. С. 69–74. DOI: 10.17650/2070-9781-2020-21-3-69-74

[33] Ghicavii V, Tanase A, Ceban E. New direction in the treatment of benign prostate hyperplasia using Adenoprosin biologically active entomological medicine. Urology. 2011;78(3):96.

[34] Ghicavii V., Tanase A., Ceban E. New direction in the treatment of benign prostate hyperplasia using Adenoprosin biologically active entomological medicine // Urology. 2011. Vol. 78, No. 3. P. 96.

[35] Saidulloev L, Ishonakov KhS, Muminov NO, et al. Effectiveness application of the adenoprosine in patients with chronic prostatitis. Vestnik Akademii meditsinskikh nauk Tadzhikistana. 2018;8(3): 361–366. (In Russ.) DOI: 10.31712/2221-7355-2018-8-3-361-368

[36] Сайдуллоев Л., Ишонаков Х.С., Муминов Н.О., и др. Эффективность применения аденопросина у больных хроническим простатитом // Вестник Академии медицинских наук Таджикистана. 2018. Т. 8, № . 3. C. 361–366. DOI: 10.31712/2221-7355-2018-8-3-361-368

[37] Kuz’min IV, Al’-Shukri SKh. Prostagut-forte in benign prostate hyperplasia therapy: is pathogenic approach? Urologicheskie vedomosti. 2012:2(3):18–23. (In Russ.)

[38] Кузьмин И.В., Аль-Шукри С.Х. Простагут-форте в терапии доброкачественной гиперплазии предстательной железы: патогенетический подход? // Урологические ведомости. 2012. Т. 2, № 3. С. 18–23.

[39] Aboyan IA, Tolmachev AN, Lemeshko SI. Morphological features of hyperplastic prostate tissue in patients with chronic prostatitis. Experimental and Clinical Urology. 2020;13(4):82–88. (In Russ.) DOI: 10.29188/2222-8543-2020-13-4-82-88

[40] Абоян И.А., Толмачев А.Н., Лемешко С.И. Морфологическая характеристика ткани гиперплазированной предстательной железы при хроническом простатите. // Экспериментальная и клиническая урология. 2020. Т. 13, № 4. С. 82–88. DOI: 10.29188/2222-8543-2020-13-4-82-88

[41] Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU. 2013;112(4):432–441. DOI: 10.1111/bju.12118

[42] Gandaglia G., Briganti A., Gontero P., et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH) // BJU. 2013;112(4):432–441. DOI: 10.1111/bju.12118

[43] Demidko YuL, Allenov SN, Uzhegov TA, Kasiteridi IG. Effektivnost’ Adenoprosina u patsientov s dobrokachestvennoi giperplaziei predstatel’noi zhelezy, khronicheskim prostatitom i simptomami nizhnikh mochevykh putei. Effektivnaya farmakoterapiya. 2021;17(3): 34–40. (In Russ.) DOI: 10.33978/2307-3586-2021-17-3-34-40

[44] Демидко Ю.Л., Алленов С.Н., Ужегов Т.А., Каситериди И.Г. Эффективность Аденопросина у пациентов с доброкачественной гиперплазией предстательной железы, хроническим простатитом и симптомами нижних мочевых путей // Эффективная фармакотерапия. 2021. Т. 17, № 3. С. 34–40. DOI: 10.33978/2307-3586-2021-17-3-34-40

[45] Medvedev VL, Efremov ME. The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis. Innovative Medicine of Kuban. 2020;(3):45–51. (In Russ.) DOI: 10.35401/2500-0268-2020-19-3-45-51

[46] Медведев В. Л., Ефремов М. Е. Эффективность применения препарата Аденопросин® в комплексном лечении пациентов с хроническим бактериальным простатитом // Инновационная медицина Кубани. 2020. № . 3. C. 45–51. DOI: 10.35401/2500-0268-2020-19-3-45-51

[47] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Entomologicheskii preparat adenoprosin v lechenii patsientov s dobrokachestvennoi giperplaziei predstatel’noi zhelezy i khronicheskim prostatitom. Urologiia. 2021;(1):39–44. (In Russ.) DOI: 10.18565/urology.2021.1.39-44

[48] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат Аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом // Урология. 2021. № . 1. С. 39–44. DOI: 10.18565/urology.2021.1.39-44

RIGHTS & PERMISSIONS

Al-Shukri A.S., Kostyukov S.V., Maksimova A.V.